UK: Cannabis-mimicking MS drug trial starts at UCLH

Warning message

The subscription service is currently unavailable. Please try again later.

Dr Rachel Farrell, consultant at UCLH's National Hospital for Neurology and Neurosurgery, is leading the innovative trial

A trial has started at UCLH of a treatment that mimics the properties of cannabis to help reduce spasticity associated with MS.

One of the most common and disabling symptoms of MS, spasticity affects up to 80 per cent of patients, causing muscle stiffness, spasms and reduced mobility. 

Many people with MS use cannabis medically to alleviate symptoms, but often suffer unwanted side effects like lethargy. Current treatments derived from cannabis are only moderately effective in reducing symptoms and also leave patients feeling fatigued and sedated. 

The new drug, discovered at UCL, is called VSN16R and does not produce the sedative effect of current drugs. It was developed with the aim of finding a synthetic compound that interacts with the body’s own cannabinoid receptors without the disadvantages of other drugs.

Our bodies produce...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.